Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery pro ...

Press ReleaseNokia and Andorix partner to accelerate Private 5G and Edge solutions in North American real estate market Private 5G, Neutral Host Network and Edge Application OT solutions enabled by Nokia Digital Automation Cloud (DAC) to enable efficient building operations and improve tenant’s satisfaction. 2 June 2025 Espoo, Finland – Nokia and Andorix, a provider of digital infrastructure and smart building solutions for real estate properties, announced a partnership to accelerate the adoption of priv ...

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord injury (SCI).Study also showed a positive trend in the secondary endpoint evaluating change in “GRASSP” score, a measure designed specifically to assess hand function in people with cervical injuries.As the first pharmaceutical candidate to show improved mot ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (Nasdaq: MRX) (“Marex”), the diversified global financial services platform, announces that it will be participating in a fireside chat at Piper Sandler's Global Exchange & Trading Conference. The presentation will be given by Ian Lowitt, Group Chief Executive Officer and will take place on Thursday, June 5th at 8:00 a.m. ET. The event will be available via webcast and can be accessed here: https://www.wsw.com/webcast/pipersandler44/marx/2943128 Ab ...

Core Insights - Lyra Therapeutics announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 for chronic rhinosinusitis (CRS), achieving its primary endpoint with significant symptom improvement compared to sham control [1][4][5] Clinical Trial Results - The ENLIGHTEN 2 trial met its primary endpoint, showing a statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at week 24 (-1.13; p=0.0078) in patients without nasal polyps [1][5] - Key secondary endpoints were also met, including a significant improvement in 3CS at 24 weeks in the full population (-0.90; p=0.0209) and in the SNOT-22 score (-8.7; p=0.0101) [2][4] - Symptom improvement was observed as early as week 4, with sustained improvements throughout the trial [2][5] Safety and Tolerability - LYR-210 was well-tolerated, with a safety profile similar to sham control and no product-related serious adverse events reported [6] - Commonly reported adverse events included epistaxis, upper respiratory tract infection, and headache [6] Future Development Plans - The company plans to review the total dataset from the ENLIGHTEN trials to evaluate next steps for pursuing an indication in non-polyp patients and to continue development in patients with nasal polyps [4][7] - Lyra aims to align with the FDA for a New Drug Application (NDA) submission for patients without nasal polyps [7] Market Potential - LYR-210 is designed to provide six months of continuous anti-inflammatory therapy with a single administration, targeting the estimated four million CRS patients in the U.S. who fail medical management each year [12]

ISS concludes that Apollo “has not presented a compelling case for change”TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services (“ISS”) published a report on May 30, 2025 (the “ISS Report”) recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees ...

Mediatiedote 2.6.2025 klo 14.00 Lassila & Tikanojan kuormalavojen korjaus- ja kierrätysliiketoiminta kasvaa Stena Recyclingin kuormalavaliiketoiminnan liiketoimintakaupan myötä 2.6.2025 alkaen Lassila & Tikanoja allekirjoitti 16.10.2024 sopimuksen Stena Recycling Oy:n kuormalavojen korjaus-, vuokraus- ja myyntiliiketoiminnan ostamisesta. Kilpailu- ja kuluttajavirasto hyväksyi liiketoimintakaupan 16.5.2025. 2.6.2025 toteutetulla kaupalla Stena Recycling Oy:n kuormalavaliiketoiminta siirtyy L&T Ympäristöp ...

Company to host conference call and webcast on June 9, 2025, at 8:00 a.m. ETSAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal ...

Core Insights - Regeneron Pharmaceuticals announced interim results from the Phase 2 COURAGE trial, showing that approximately 35% of weight loss from semaglutide was due to lean mass loss, and combining it with trevogrumab helped preserve lean mass while increasing fat loss [1][2][3] Group 1: Trial Results - The COURAGE trial demonstrated that combining semaglutide with trevogrumab, with or without garetosmab, preserved 50%-80% of lean mass compared to semaglutide alone while enhancing fat mass loss [1][2] - At the 26-week interim analysis, patients receiving semaglutide alone lost an average of 7.9 lbs of lean mass, while those on the lower-dose and higher-dose combinations lost 3.7 lbs and 4.2 lbs respectively, and the triplet group lost only 2.0 lbs [3][4] - Fat mass loss was significantly higher in combination groups, with the triplet group losing an average of 25.4 lbs, representing an 84.4% change from baseline [3][4] Group 2: Safety and Tolerability - The combination therapies were generally well-tolerated, but the triplet combination had a higher rate of treatment discontinuation due to tolerability issues, with 28.3% of participants discontinuing treatment [1][6] - The overall incidence of treatment-emergent adverse events (TEAEs) was 64.9% for semaglutide monotherapy, increasing to 77.2% in the triplet group [6] Group 3: Future Directions - The full data set from the COURAGE trial is expected to be available later this year, which will provide further insights for optimizing dosing regimens in future trials [2] - Regeneron is focused on developing treatments that improve the quality of weight loss by preserving muscle mass during weight reduction, addressing a significant concern in obesity management [7][8]

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference. 2024 Jefferies Global Healthcare ConferenceFir ...